Hirohito Yamaguchi

13.5k total citations · 6 hit papers
102 papers, 7.8k citations indexed

About

Hirohito Yamaguchi is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Hirohito Yamaguchi has authored 102 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Molecular Biology, 34 papers in Oncology and 18 papers in Immunology. Recurrent topics in Hirohito Yamaguchi's work include Cell death mechanisms and regulation (18 papers), Cancer-related Molecular Pathways (10 papers) and Reproductive System and Pregnancy (8 papers). Hirohito Yamaguchi is often cited by papers focused on Cell death mechanisms and regulation (18 papers), Cancer-related Molecular Pathways (10 papers) and Reproductive System and Pregnancy (8 papers). Hirohito Yamaguchi collaborates with scholars based in United States, Taiwan and Japan. Hirohito Yamaguchi's co-authors include Hong‐Gang Wang, Mien‐Chie Hung, Jung-Mao Hsu, Kapil N. Bhalla, Jennifer L. Hsu, Heng‐Huan Lee, Ying‐Nai Wang, Yi Du, Katsuya Nakai and Gabriel N. Hortobágyi and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and SHILAP Revista de lepidopterología.

In The Last Decade

Hirohito Yamaguchi

101 papers receiving 7.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression

2017 768 citations Shiping Jiao, Weiya Xia et al. Clinical Cancer Research profile →
CHOP Is Involved in Endoplasmic Reticulum Stress-induced Apoptosis by Enhancing DR5 Expression in Human Carcinoma Cells

2004 673 citations Hirohito Yamaguchi, Hong‐Gang Wang Journal of Biological Chemistry profile →
Molecular Cloning and Characterization of Bif-1

2001 508 citations Hirohito Yamaguchi, Hong‐Gang Wang et al. Journal of Biological Chemistry profile →
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics

2022 347 citations Hirohito Yamaguchi, Jung-Mao Hsu et al. profile →
TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis

2021 255 citations Seung-Oe Lim, Jennifer L. Hsu et al. profile →
Advances and prospects of biomarkers for immune checkpoint inhibitors

2024 50 citations Hirohito Yamaguchi, Jung-Mao Hsu et al. profile →

Peers

Countries citing papers authored by Hirohito Yamaguchi

Since Specialization

Citations

This map shows the geographic impact of Hirohito Yamaguchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hirohito Yamaguchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hirohito Yamaguchi more than expected).

Fields of papers citing papers by Hirohito Yamaguchi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hirohito Yamaguchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hirohito Yamaguchi. The network helps show where Hirohito Yamaguchi may publish in the future.

Co-authorship network of co-authors of Hirohito Yamaguchi

This figure shows the co-authorship network connecting the top 25 collaborators of Hirohito Yamaguchi. A scholar is included among the top collaborators of Hirohito Yamaguchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hirohito Yamaguchi. Hirohito Yamaguchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	KMT2C mutations in breast cancer: molecular mechanisms of cancer promotion, clinical significance, and potential as biomarkers 2025 ·Critical Reviews in Oncology/Hematology ·Ming‐Chuan Hsu, Yu-Fu Chen, Hirohito Yamaguchi	0
2	Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer 2024 ·Cancer Letters ·Parham Jabbarzadeh Kaboli, Hsiao‐Fan Chen, (unknown), (unknown), Hirohito Yamaguchi, Mien‐Chie Hung	19
3	Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy 2024 ·Cancer Research ·Te-An Lee, (unknown), (unknown), (unknown), Shing‐Jyh Chang, Chi-Hong Chao, Yun‐Ju Lai, Hirohito Yamaguchi, (unknown)	30
4	Prospects of the potential strategies to improve the efficacy of anti‐PD‐1/PD‐L1 therapy 2022 ·Clinical and Translational Medicine ·Hirohito Yamaguchi, Shao‐Chun Wang, Mien‐Chie Hung	5
5	Isolation of cancer-derived extracellular vesicle subpopulations by a size-selective microfluidic platform 2020 ·Biomicrofluidics ·(unknown), Yi Yang, Hirohito Yamaguchi, Mien‐Chie Hung, Jun Kameoka	37
6	Estrogen promotes increased breast cancer cell proliferation and migration through downregulation of CPEB1 expression 2020 ·Biochemical and Biophysical Research Communications ·(unknown), (unknown), (unknown), (unknown), Tomoyuki Fujita, Gen Watanabe, Hirohito Yamaguchi, Kentaro Nagaoka	7
7	MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1 2019 ·Gastroenterology ·Hui Li, Chia‐Wei Li, Xiaoqiang Li, Qingqing Ding, (unknown), Shuang Liu, Chunxiao Liu, Chien‐Chen Lai, Jung-Mao Hsu, Qiongzhu Dong, Weiya Xia, Jennifer L. Hsu, Hirohito Yamaguchi, Yi Du, Yun‐Ju Lai, Xian Wen Sun, Paul Koller, Qing‐Hai Ye, Mien‐Chie Hung	154
8	EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma 2018 ·Cancer Research ·Qiongzhu Dong, Yi Du, Hui Li, Chunxiao Liu, Yongkun Wei, Mei‐Kuang Chen, Xixi Zhao, Yu‐Yi Chu, Yufan Qiu, Lun–Xiu Qin, Hirohito Yamaguchi, Mien‐Chie Hung	59
9	PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression breakdown → 2017 ·Clinical Cancer Research ·Shiping Jiao, Weiya Xia, Hirohito Yamaguchi, Yongkun Wei, Mei‐Kuang Chen, Jung-Mao Hsu, Jennifer L. Hsu, Wen-Hsuan Yu, Yi Du, Heng‐Huan Lee, Chia‐Wei Li, Chao‐Kai Chou, Seung-Oe Lim, Sam S. Chang, Jennifer K. Litton, Banu Arun, Gabriel N. Hortobágyi, Mien‐Chie Hung	768
10	Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non–Small Cell Lung Cancer Cells 2013 ·Clinical Cancer Research ·Hirohito Yamaguchi, Jennifer L. Hsu, Chun‐Te Chen, Ying‐Nai Wang, Ming‐Chuan Hsu, Sam S. Chang, Yi Du, How-Wen Ko, Roy S. Herbst, Mien‐Chie Hung	110
11	Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer 2012 ·Molecular Cancer Therapeutics ·Chun‐Te Chen, Yi Du, Hirohito Yamaguchi, Jung-Mao Hsu, Hsu-Ping Kuo, Gabriel N. Hortobágyi, Mien‐Chie Hung	21
12	Epithelial–Mesenchymal Transition Induced by TNF-α Requires NF-κB–Mediated Transcriptional Upregulation of Twist1 2012 ·Cancer Research ·Chia‐Wei Li, Weiya Xia, Longfei Huo, Seung-Oe Lim, Yun Wu, Jennifer L. Hsu, Chi-Hong Chao, Hirohito Yamaguchi, (unknown), Qingqing Ding, Yan Wang, Yun‐Ju Lai, Adam M. LaBaff, (unknown), Been‐Ren Lin, Muh‐Hwa Yang, Gabriel N. Hortobágyi, Mien‐Chie Hung	389
13	Membrane-bound Trafficking Regulates Nuclear Transport of Integral Epidermal Growth Factor Receptor (EGFR) and ErbB-2 2012 ·Journal of Biological Chemistry ·Ying‐Nai Wang, Heng‐Huan Lee, Hong-Jen Lee, Yi Du, Hirohito Yamaguchi, Mien‐Chie Hung	62
14	Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase 2011 ·Molecular Cancer Therapeutics ·Chun‐Te Chen, Hirohito Yamaguchi, Hong-Jen Lee, Yi Du, Heng‐Huan Lee, Weiya Xia, Wen-Hsuan Yu, Jennifer L. Hsu, Chia-Jui Yen, Hui-Lung Sun, Yan Wang, Edward T.H. Yeh, Gabriel N. Hortobágyi, Mien‐Chie Hung	21
15	FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization 2011 ·Cancer Research ·Jen-Liang Su, Xiaoyun Cheng, Hirohito Yamaguchi, Yi-Wen Chang, (unknown), Dung‐Fang Lee, How-Wen Ko, Kuo‐Tai Hua, Ying‐Nai Wang, Michael Hsiao, Poshen B. Chen, Jung-Mao Hsu, Robert C. Bast, Gabriel N. Hortobágyi, Mien‐Chie Hung	39
16	Measurement of Protein 53 Diffusion Coefficient in Live HeLa Cells Using Raster Image Correlation Spectroscopy (RICS) 2010 ·Journal of Biomaterials and Nanobiotechnology ·Sungmin Hong, Ying‐Nai Wang, Hirohito Yamaguchi, (unknown), Chao‐Kai Chou, (unknown), Mien‐Chie Hung, Jun Kameoka	7
17	A novel hTERT promoter–driven E1A therapeutic for ovarian cancer 2009 ·Molecular Cancer Therapeutics ·Xiaoming Xie, Jennifer L. Hsu, Min Gew Choi, Weiya Xia, Hirohito Yamaguchi, Chun‐Te Chen, (unknown), Zhen Lü, Naoto T. Ueno, Judith K. Wolf, Robert C. Bast, Mien‐Chie Hung	30
18	EPOX Inhibits Angiogenesis by Degradation of Mcl-1 through ERK Inactivation 2009 ·Clinical Cancer Research ·Hui-Lung Sun, An‐Chi Tsai, Shiow‐Lin Pan, Qingqing Ding, Hirohito Yamaguchi, Chun-Nan Lin, Mien‐Chie Hung, Che‐Ming Teng	20
19	Anoikis, Initiated by Mcl-1 Degradation and Bim Induction, Is Deregulated during Oncogenesis 2007 ·Cancer Research ·Nicholas T. Woods, Hirohito Yamaguchi, Francis Y. Lee, Kapil N. Bhalla, Hong‐Gang Wang	87
20	Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2 2005 ·Clinical Cancer Research ·Purva Bali, Michael Pranpat, Ramona F. Swaby, Warren Fiskus, Hirohito Yamaguchi, Maria E. Balasis, Kathy Rocha, Hong‐Gang Wang, Victoria M. Richon, Kapil N. Bhalla	156

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact